JPRN-UMIN000016416已完成2 期
PhaseII study of mFOLFOX6 in gastric cancer refractory to standard therapy - PhaseII study of mFOLFOX6 in gastric cancer refractory to standard therapy
Aichi Cancer Center Hospital0 个研究点目标入组 35 人开始时间: 2015年2月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with symptomatic brain metastases. 2) Requires perodial drainage of pleural fluid, ascites or pericardial effusion. 3) Received chemotherapy, radiotherapy, surgical or any other experimental therapies as anticancer treatment within 14 days before the first administration of this trial. 4) Previous treatment with oxaliplatin. 5) Concurrent uncontrolled medical condition including active infection, hypertension, diabetes mellitus, pulmonary, cardiac or psychiatric disease 5) known or suspected of not being able to comply with this trial protocol.
研究者
相似试验
已完成
2 期
Multicancer Phase II study of mFOLFOX6 as Neoadjuvant chemotherapy for T3 or T4 Stage II / III rectal cancerRectal CancerJPRN-UMIN000006583Tokyo Women's Medical University Hospital50
已完成
2 期
Phase II trial of adjuvant mFOLFOX6 after metastasectomy for lung metastasis of colorectal cancerColorectal cancerJPRN-UMIN000005693West Japan Oncology Group100
已完成
2 期
A phase II study of mFOLFOX6 in gastric cancer with severe peritoneal metastasisgastric cancerJPRN-jRCTs041180007Masuishi Toshiki51
招募中
2 期
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)Gastric Carcinoma Stage IVEsophagogastric Junction Adenocarcinoma Stage IVNCT04442984Blokhin's Russian Cancer Research Center326
终止
2 期
FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal AdenocarcinomaMetastatic Gastro-esophageal AdenocarcinomaNCT03528876University of Saskatchewan36